1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6985A7D55BC5372F385257D8200549250
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-medical-affairs-excellence-global-coordination-managing-compliance?opendocument
18
19opendocument
2035.175.191.72
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services Medical Affairs Medical Affairs Excellence

Medical Affairs Excellence: Global Coordination and Managing Compliance

ID: 5334


Features:

9 Info Graphics

17 Data Graphics

250+ Metrics

6 Narratives


Pages/Slides: 33


Published: 2014


Delivery Format: Online PDF Document


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from "Medical Affairs Excellence: Global Coordination and Managing Compliance"


STUDY OVERVIEW

Medical Affairs has evolved into one of the most critical functions for the pharmaceutical sector. As its importance and duties have grown, Medical Affairs has faced many challenges in creating and maintaining the function as a global group.

Best Practices, LLC conducted this study to identify what companies require in order to create effective global capabilities for the Medical Affairs function. The study also reviews how companies are coordinating compliance standards across different geographies.

The benchmark data in this study will help companies find better ways to create successful global Medical Affairs organizations.

This study presents segmented responses by company size

KEY TOPICS

  • Coordinating the Global Medical Affairs Function
  • Managing Compliance and Information Exchange
  • Benchmark Participant Demographics

SAMPLE KEY METRICS
  • Management approach for key Medical Affairs activities
  • Reporting relationship between global and regional Medical Affairs groups
  • How regions develop their compliance standards
  • How regions identify their compliance standards
  • How regions identify their compliance standards
  • How organizations share compliance challenges and best practices across global and regional levels

SAMPLE KEY FINDING
    • Global Coordination: More than 80% of the benchmark class employs a bottom-up reporting approach for the activities related to payers and providers, such as medical education, field-based medical team operations, and thought leader management. Although some of the interviewees think that developing a top-down approach is ideal to avoid compliance issues and promote better communication for payer and provider related activities, local differences such as, language, culture and regulations force companies to employ a bottom-up approach for these activities.
        • Segments: Global reporting approach to Medical Affairs resources allocation is significantly different across segments. While 88% of the LCS employs a bottom-up approach, only 50% of the MCS & SCS has a similar approach for this activity.
METHODOLOGY

Twenty Nine survey responses from Medical Affairs leaders at 26 biopharmaceutical companies within the mature markets. This reports captures insights on both Large and Mid-Size as well as Small companies segments. Additional deep-dive interviews with five selected Medical Affairs executives.

Industries Profiled:
Biotech; Pharmaceutical; Manufacturing; Consumer Products; Diagnostic; Medical Device; Health Care; Biopharmaceutical; Clinical Research; Laboratories


Companies Profiled:
Amgen; Axon Pharma; Astellas; Insys Therapeutics; AstraZeneca; Xenoport; Baxter BioScience; Bayer; Biogen Idec; Boehringer Ingelheim; Eisai; Ipsen; Janssen; Jazz Pharmaceuticals; Eli Lilly; Lundbeck; Medunik; Merck; Merz Pharma; Onyx Pharmaceuticals; Purdue Pharma; Sanofi; Theravance; UCB Pharma; Upsher-Smith; ViiV Healthcare

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.